3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (July 2019)
39 slides from 3b Blackbio Dx's investor presentation, Jul 29, 2019
Slide 1: Kilpest India Limited covering letter
KILPEST INDIA LIMITED REGD. OFFICE & FACTORY : 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA) Tel : (91-755) 2586536, 2586537 FAXNO. : (91-755) 2580438 ; Email : kilpest@bsni.in visit us at : www.kilpest.com kilpestbpl@yahoo.co.in CIN : L24211MP1972PLC001131 Ref. No.P-66/ July 29, 2019 T
Slide 2: Investor Presentation July 2019
Farmers trusted Agro-input partner for 46 years Reliable & affordable healthcare diagnostics solutions INVESTOR PRESENTATION JULY 2019
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of art facility located in center of India- with GST implementation this should give a boost to the company • 46yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhya
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights KILPEST (Consolidated) Q1 F20 Q1 FY19 562.87 36.82% 61.59% 196.53 Net sales (FY18 net of Excise Duty) 562.87 411.40 411.4 Q1F20 121.62 Profit before tax 196.53 121.62 Q1F19 Profit after tax 142.03 87.86 Revenue PBT Paid up Equity share capital 750.81 640.81 (CO
Slide 7: Present Market Overview/Outlook
Present Market Overview/Outlook • This year monsoon has been delayed which will affect sales of the company. • Company with its focus on public health and export business will be able to ward off ill effects of delayed monsoon. • With reduced debt company this year will have substantial saving on in
Slide 8: From the house of KILPEST INDIA LTD.
Since 1972 From the house of KILPEST India Ltd., India’s most trusted agro-chemical KILPEST INDIA brand proudly brings LTD. First licensed IVD manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 9: From the house of KILPEST India Ltd.
From the house of KILPEST India Ltd. 3B BlackBio Biotech India Limited; has become India’s leading healthcare company specialized in the development of molecular biology fine-chemicals as tools for diagnostic/pathology segment of healthcare. The Company is CDSCO Licensed, ISO 13485:2016 certified, G
Slide 10: TRUPCR from 3B BlackBio Biotech: Vision and Mission
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Vision Reliable and affordable healthcare solutions for all Mission 3B BlackBio Biotech (I) Ltd. with its TRUPCR® brand of products is committed to design and develop molecular diagnostics products of superior quality and value that continuously improves the
Slide 11: Timeline & Milestones
Timeline & Milestones Launching Oncopanels Launch of Solid Extending Menu Tumor AML with Virology & ALL Public Health EGFR MPN KRAS Adding Virology HBV, HCV Acquisition of & Expanding HCV Genotyping NGS Menu HIV1/2 Dengue, Entering Oncology & H1N1 HBV Chikungunya Human First product HCV Inception of
Slide 12: Growth Canvas
Growth Canvas Sales (Rs. In Lakhs) Customers ₹1,200.00 160 ₹1,118.93 140 ₹1,000.00 120 ₹800.00 ₹765.05 100 ₹600.00 80 60 ₹400.00 ₹315.89 40 ₹200.00 ₹164.56 ₹94.56 ₹100.73 20 ₹0.00 0 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 Sales (Rs. In Lakhs) ₹94.56 ₹100.73 ₹164.56 ₹315.89 ₹765.05 ₹1,118.93
Slide 13: Financial Highlights Q1-FY20
Financial Highlights Q1-FY20 324.21 56.10% 57.16% 202.05 207.7 128.56 Revenue EBITDA 194.55 140.42 61.08% 61.07% 120.78 87.18 Q1FY20 Q1FY19 PBT Rs. In Lakhs. PAT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 14: Our Beneficiaries
Our Beneficiaries FOR PATIENTS FOR LABORATORIES CLINICALLY VALIDATED PRECISE TRUPCR® kits are calibrated to WHO standards and clinically validated TRUPCR® offers highly sensitive and precise qPCR assays as on wide variety and numbers of samples. indicated by minimum variability of replicates and mul
Slide 15: Our Team
Our Team • A team of highly motivated individuals who seek to bring a positive change in the lives of people through their hard work and dedication. • We are a group of molecular biologists working towards a common goal of developing reliable molecular tools which can help healthcare practitioners t
Slide 16: Work Process
Work Process PLAN RESEARCH Feasibility DESIGN DEVELOP VALIDATIONS APPROVALS COMMERCIALIZATION (Technical & Commercial) IMPROVEMENT SUPPORT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 17: R&D People and Laboratory Infrastructure
R&D People • Highly educated team of scientist from varied backgrounds • Dedicated teams for respective segments • Separate onco team headed by researchers (Ph.Ds.) from oncology background • Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 18: Product QC – Our Strength
Product QC – Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 19: Our Certificates
Our Certificates ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 20: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Sanger Sequencing Next Generation Mass Spec Sequencing Hybridization Microarray Low Volume ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 21: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express the
Slide 22: Molecular diagnostics market size source
Source-https://www.gminsights.com/pressrelease/molecular-diagnostics-market-size
Slide 23: Product Segments
Product Segments Molecular Microbiology Molecular Oncology Human Genetics SYNDROMES & INFECTIONS CANCERS DISORDERS Individual Markers Individual Markers Individual Markers Infectious Panels Oncology Panels Genetic Panels ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALT
Slide 24: Product Range
Product Range ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 25: Product Range
Product Range ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 26: All-Inclusive TRUPCR products
All-Inclusive TRUPCR® products TRUPCR range of products offers end-to-end standardized solutions from samples to optimized end -results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis TRUPCR Nucleic Acid Extraction k
Slide 27: Next Generation Sequencing Assays
Next Generation Sequencing Launching soon… Next Generation Sequencing Assays Real image of NGS facility at 3B BlackBio Biotech (I) Ltd. Bhopal, India ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 28: Product Pipeline
Product Pipeline RESEARCH DEVELOPMENT VALIDATION / TRIALS COMMERCIALIZATION qPCR Assays - Solid Tumours and Liquid Biopsy 2019 qPCR Assays - Infectious Panels 2019/20 NGS Assays – Solid Tumours 2020 ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 29: Our National Presence
Our National Presence TRUPCR® range of products are currently used by: 155+ customers Across 40 Cities ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 30: Our Global Presence
Our Global Presence And NOW !!! TRUPCR® is gaining its global footprints With High Sub-Continent presence with Neighbouring Countries And Also started business with customers across South East Asia & Middle East Products undergoing Validation in USA Final stage price negotiation in Latin America & S
Slide 31: New Customers added in Q1 2019-20
New Customers added in Q1 2019-20 One Diagnostic Laboratory Assam One Diagnostic Laboratory Kolkata Two Diagnostic Laboratory Bangladesh One Diagnostic Laboratory Mumbai One Diagnostic Laboratory Madhya Pradesh Several Parameters started with Existing Customers
Slide 32: New Products Launched in 2019
New Products Launched in 2019 • TRUPCR® Chikungunya/ Dengue & Zika virus Kit- Detection Kit Detection of Chikungunya/ Dengue & Zika virus on real-time PCR • TRUPCR® Rif/ INH MTB Drug Resistance Detection Kit – Detection of MTBC and resistance to Rifampicin & Isoniazid using real-time PCR • TRUPCR® A
Slide 33: Target Customer Segments
Target Customer Segments Indian IVD/MDx Market Hospital Labs Stand-alone Pharma Labs Govt. Private Pathologist(s) Corporate CLINICAL Hospitals Hospitals Labs Labs TRIALS Secondary Central Govt. State Govt. Corporate Other Private Targeted National Regional National Labs Regional Labs Hospitals Hospi
Slide 34: TRUPCR Global Recognition
TRUPCR® Global Recognition Complete Includes Simultaneous Location of workflow Reverse Alignment step for Major Company Sensitivity Company solution Transcriptase with IS and Minor available step design transcript France, Europe Elitech - PCR alert kit MR4.0 ✗ ✗ WHO ✗ 3B BlackBio - TRUPCR® INDIA MR4
Slide 35: Contractual Business and Tender Business
Contractual Business • We are happy to inform that the Company to ensure long term assured business, has started signing long term (2-3 yr) contract with large customers. • As on date the company has six contracts running, which ensures yearly business of up to Rs. 40-45 Million total from these six
Slide 36: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs External Growth • Evolution of disease profiles. New viruses and cancers are been diagnosed Drivers • Increase in evidence-based treatments /
Slide 37: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 38: Outstanding Achievement Award for Excellence in R&D
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 39: Thank You
Thank You ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH